Literature DB >> 3999461

Estimation of plasma and urinary catecholamines in Guillain-Barré syndrome.

J Ahmad, A S Kham, M A Siddiqui.   

Abstract

Serial estimation of plasma nor-epinephrine (PNE), 24 hours urinary vanilmandelic acid (VMA) and plasma cortisol was made in 25 adult patients of Guillain-Barré syndrome. Healthy adult age and sex matched volunteers served as controls. The mean level of PNE, VMA and plasma cortisol in controls was 1.07 +/- 0.50 ng/ml, 2.81 +/- 1.18 mg/24 hours and 12.9 +/- 3.10 micrograms/100 ml, respectively. In cases of Guillain-Barré syndrome with autonomic dysfunction the mean level of PNE, VMA and plasma cortisol was 3.34 +/- 2.47 ng/ml, 7.98 +/- 5.71 mg/24 hours and 27.25 +/- 4.94 micrograms/100 ml on the day of admission while in cases of Guillain-Barré syndrome without autonomic dysfunction it was 1.09 +/- 0.32 ng/ml, 3.04 +/- 2.22 mg/24 hours and 11.8 +/- 4.2 micrograms/100 ml, respectively. An increase in circulating PNE, VMA and plasma cortisol was demonstrated in patients of Guillain-Barré syndrome with autonomic dysfunction presenting as hypertension and tachycardia. The maximum rise of 284% (PNE) and 253% (VMA) occurred at the height of paralysis. The elevated levels fell to near control values at the time of significant recovery, and glucose tolerance tests improved. It is suggested that increased levels of catecholamines and cortisol contributed to the development of dysautonomia as these levels were within normal limits in patients of Guillain-Barré syndrome without autonomic dysfunction.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3999461     DOI: 10.2169/internalmedicine1962.24.24

Source DB:  PubMed          Journal:  Jpn J Med        ISSN: 0021-5120


  8 in total

Review 1.  Guillain-Barré syndrome.

Authors:  U Seneviratne
Journal:  Postgrad Med J       Date:  2000-12       Impact factor: 2.401

2.  Bladder dysfunction and hypertension in children with Guillain-Barre syndrome.

Authors:  Louise Watson; Majid Aziz; Grace Vassallo; Nicholas D Plant; Nicholas J A Webb
Journal:  Pediatr Nephrol       Date:  2014-03-22       Impact factor: 3.714

3.  Guillain-Barré syndrome as a cause of reversible cardiomyopathy.

Authors:  Jason S Finkelstein; Bekir H Melek
Journal:  Tex Heart Inst J       Date:  2006

4.  Intrapulmonary right-left shunts in Guillain-Barré syndrome with severe dysautonomia.

Authors:  Marek Sykora; Jennifer Diedler; Werner Hacke; Roland Veltkamp
Journal:  Neurocrit Care       Date:  2008       Impact factor: 3.210

Review 5.  Autonomic involvement in Guillain-Barré syndrome: an update.

Authors:  Zoya Zaeem; Zaeem A Siddiqi; Douglas W Zochodne
Journal:  Clin Auton Res       Date:  2018-07-17       Impact factor: 4.435

Review 6.  Roles of catechol neurochemistry in autonomic function testing.

Authors:  David S Goldstein; William P Cheshire
Journal:  Clin Auton Res       Date:  2018-04-28       Impact factor: 4.435

7.  Severe bradycardia in a teenager as the initial manifestation for Guillain Barré syndrome: a case report.

Authors:  C Bonilla; M I Alvarez-Olmos; C Uribe; J Fernández-Sarmiento
Journal:  BMC Pediatr       Date:  2022-03-22       Impact factor: 2.125

8.  Guillain-Barre syndrome with posterior reversible encephalopathy syndrome.

Authors:  Basavaraj F Banakar; Guruprasad S Pujar; Amita Bhargava; Shubhkaran Khichar
Journal:  J Neurosci Rural Pract       Date:  2014-01
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.